* WAVE Life Sciences Ltd WVE.OQ reported a quarterly
adjusted
loss of 25 cents per share for the quarter ended in June,
lower than the same quarter last year, when the company reported
EPS of -20 cents. The mean expectation of seven analysts for
the quarter was for a loss of 21 cents per share. Wall Street
expected results to range from -34 cents to -8 cents per share.
* Revenue fell 10.9% to $19.69 million from a year ago;
analysts
expected $24.34 million.
* WAVE Life Sciences Ltd's reported EPS for the quarter was
a loss
of 25 cents.
* The company reported a quarterly loss of $32.92 million.
* WAVE Life Sciences Ltd shares had risen by 19.8% this
quarter and gained 18.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 8.8%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for WAVE Life
Sciences Ltd is $15.00
This summary was machine generated from LSEG data August 8 at
01:31 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.21 -0.25 Missed
Mar. 31 2024 -0.21 -0.24 Missed
Dec. 31 2023 -0.23 -0.15 Beat
Sep. 30 2023 -0.18 0.07 Beat